Collectively, HJ901 treatment may have reduced IL-6 and IL-10 secretion in cells and suppressed cell proliferation and tumor growth in cells and mice through possible mechanisms that modulate the TLR7/9, NF-κB, and JAK2-STAT3 signaling pathways. The gene discussed is JAK2; the disease is neoplasm.